RTI aims to make the first MAPC technology-based implants available for use in orthopedic surgery in early 2012.
Athersys stands to earn another $2 million in development and commercialization milestones and $35.5 million in cumulative revenue milestones, according to the report.
Read the Genetic Engineering and Biotechnology News report on the RTI, Athersy’s deal.
Read other coverage on orthopedic devices:
– Orthopedic Implant Device Can Increase Bone Length
– Top 5 Orthopedic Device Companies Based on 2009 Revenues
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
